Solution-Phase Synthesis of Wnt Hexapeptide Foxy-5
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current solid phase peptide synthesis methods for producing Foxy-5, a Wnt5a-derived hexapeptide, are not scalable for large-scale clinical and commercial production, leading to high costs and inefficiencies in producing sufficient quantities for further clinical studies and commercial purposes.
Innovation Solution
Development of solution-phase methods for synthesizing Foxy-5 using fragment coupling strategies such as 2+2+2, 3+3, 4+1+1, and 3+1+1 approaches, which allow for the assembly of the peptide through the coupling of dipeptides or tripeptides, enabling easier purification and scalability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If solid phase peptide synthesis (SPPS) is used to produce Foxy-5, then the peptide can be synthesized with controlled sequence and high purity, but the production is not scalable for large-scale clinical and commercial purposes, leading to high costs and inefficiencies
Solution Approach 1:
The patent divides the hexapeptide synthesis into separate dipeptide and tripeptide fragments that are synthesized independently and then coupled together. This segmentation allows each fragment to be optimized separately and facilitates scaling by enabling parallel synthesis and easier purification of intermediates, directly resolving the contradiction between maintaining precision and improving productivity.
2Ease of manufacture
If solid phase peptide synthesis is used, then the synthesis can proceed through alternating coupling and deprotection steps, but the method is not adaptable to commercial scale-up and involves complex purification procedures
Solution Approach 1:
The patent transitions from solid phase to solution phase synthesis, fundamentally changing the physical state parameter of the reaction medium. This parameter change enables the use of fragment coupling strategies that are more adaptable to commercial scale-up, allowing for easier purification through precipitation and filtration rather than the complex resin-based purification required in SPPS.
3Manufacturing precision
If linear 1+1+1+1+1+1 assembly route is used on resin, then the peptide sequence can be built step-by-step with systematic acetylation, but the raw material costs are high and the process is inefficient for large-scale production
Solution Approach 1:
The patent merges multiple small peptide fragments (dipeptides and tripeptides) into the final hexapeptide through coupling reactions. This merging approach reduces raw material costs by enabling the use of simpler, more cost-effective starting materials and reducing the need for expensive resin and reagents required in linear SPPS, while maintaining systematic control through the fragment assembly strategy.
Data Source
AI summary
The present disclosure relates generally to the field of polypeptide synthesis, and more particularly, to the solution phase synthesis of the Wnt hexapeptide Foxy-5 and protected derivatives and peptide fragments thereof.